Tag: Biotech and Pharma

A bipartisan group of U.S. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved ​in clinical trials conducted in China that helped fuel the communist country’s military capability, according to letters seen by Reuters.

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the drug’s future.

Σύμφωνα με τα στοιχεία που παρουσιάστηκαν, οι πωλήσεις στο πρώτο εξάμηνο κινούνται με ρυθμό ανόδου της τάξης του 24%, επιβεβαιώνοντας τη δυναμική που έχει αναπτύξει ο όμιλος σε βασικές κατηγορίες προϊόντων και αγορές.

 AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, ​in its largest buyout in more than five years to strengthen its next-gen ‌immunology pipeline.

Britain’s second-largest drugmaker GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what would be its largest acquisition in more than a decade.

Eli Lilly shares jumped in premarket trade on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.

Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data on its experimental medicine raised concerns over its potential side effects.

Moderna said on Monday it has ​partnered with a global health coalition to develop a potential ‌vaccine against Bundibugyo ebolavirus, the strain linked to the ongoing Ebola outbreak in eastern Democratic Republic of Congo.

Η Lavipharm Α.Ε. ανακοινώνει την ολοκλήρωση της συναλλαγής για την απόκτηση των Αδειών Κυκλοφορίας, των εμπορικών σημάτων και των δικαιωμάτων εμπορικής εκμετάλλευσης και παραγωγής του DUROGESIC® από την Janssen Global Services LLC

Eli Lilly & Co. agreed to buy three vaccine developers for a total of up to about $3.8 billion, marking the drugmaker’s re-entry into the infectious disease space.

Biogen (BIIB.O), will advance its experimental Alzheimer’s drug to late-stage ​development after a mid-stage study showed it slowed mental decline and reduced ‌a key brain protein linked to the disease, although it failed to meet the trial’s main goal.

Telehealth company Hims & Hers’ stock plummeted in early trading Tuesday after posting a first-quarter loss and weak earnings guidance for the year ahead.

Novo Nordisk, opens new tab beat first-quarter profit forecasts and nudged up its full-year outlook on Wednesday, helped by stronger-than-expected sales of its new weight-loss pill ‌as it seeks to close the gap with U.S. rival Eli Lilly.

Pfizer shares climbed on Tuesday after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook.

Moderna defied expectations of a Covid-revenue slowdown on Friday as the drugmaker delivered strong first-quarter results fueled by a surge in international vaccine sales.

Bristol-Myers Squibb reported first-quarter earnings and revenue that topped analyst expectations, and reaffirmed its outlook for the full year.

Shares of Eli Lilly (LLY) rose sharply Thursday after the drugmaker delivered a beat-and-raise quarter driven partly by demand for its GLP-1 drugs.

GSK (GSK) reported higher earnings on increased specialty medicine sales and said it expects to pay a total dividend this year of 70 pence a share.

AstraZeneca (AZN)  beat first-quarter profit expectations and maintained its 2026 forecasts on Wednesday, supported by strong demand for its cancer and rare-disease drugs and investments in the key U.S. and China markets.

Novartis (NOVN) reported a drop in earnings as generic competition for its top-selling heart drug Entresto hit sales in the first months of the year.